Abstract
FDA on February 8 announced the approval of pomalidomide, a thalidomide analog, as a treatment for multiple myeloma that has progressed after previous therapies. Labeling for pomalidomide states that the drug is indicated in patients who have undergone at least two cycles of therapy for multiple
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
